-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Magnus Financial Group LLC Lowers Stake in Aprea Therapeutics, Inc. (NASDAQ:APRE)
Magnus Financial Group LLC Lowers Stake in Aprea Therapeutics, Inc. (NASDAQ:APRE)
Magnus Financial Group LLC lessened its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) by 56.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 14,856 shares of the company's stock after selling 19,125 shares during the quarter. Magnus Financial Group LLC's holdings in Aprea Therapeutics were worth $28,000 at the end of the most recent quarter.
Separately, PDT Partners LLC lifted its holdings in shares of Aprea Therapeutics by 62.5% in the 4th quarter. PDT Partners LLC now owns 142,600 shares of the company's stock worth $409,000 after buying an additional 54,866 shares during the period. 18.95% of the stock is owned by institutional investors and hedge funds.
Get Aprea Therapeutics alerts:Analyst Upgrades and Downgrades
Separately, Wedbush started coverage on Aprea Therapeutics in a research note on Thursday, July 7th. They set an "outperform" rating and a $3.00 price target on the stock.
Aprea Therapeutics Stock Performance
NASDAQ APRE opened at $0.78 on Friday. The company has a market cap of $18.25 million, a PE ratio of -0.14 and a beta of 0.63. The firm's 50 day moving average price is $0.93 and its 200-day moving average price is $1.24. Aprea Therapeutics, Inc. has a 52-week low of $0.62 and a 52-week high of $5.67.About Aprea Therapeutics
(Get Rating)
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
Read More
- Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding APRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating).
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Magnus Financial Group LLC lessened its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) by 56.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 14,856 shares of the company's stock after selling 19,125 shares during the quarter. Magnus Financial Group LLC's holdings in Aprea Therapeutics were worth $28,000 at the end of the most recent quarter.
据HoldingsChannel报道，Magnus Financial Group LLC在第一季度减持了Aprea治疗公司(纳斯达克：APRE-GET评级)56.3%的股份。该机构投资者在本季度出售了19,125股后，持有14,856股该公司股票。截至最近一个季度末，Magnus Financial Group LLC持有的Aprea治疗公司股份价值2.8万美元。
Separately, PDT Partners LLC lifted its holdings in shares of Aprea Therapeutics by 62.5% in the 4th quarter. PDT Partners LLC now owns 142,600 shares of the company's stock worth $409,000 after buying an additional 54,866 shares during the period. 18.95% of the stock is owned by institutional investors and hedge funds.
另外，PDT Partners LLC在第四季度增持了Aprea Treateutics的股票62.5%。在此期间，PDT Partners LLC又购买了54,866股，现在拥有142,600股该公司股票，价值409,000美元。18.95%的股票由机构投资者和对冲基金持有。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, Wedbush started coverage on Aprea Therapeutics in a research note on Thursday, July 7th. They set an "outperform" rating and a $3.00 price target on the stock.
另外，韦德布什在7月7日星期四的一份研究报告中开始报道Aprea治疗公司。他们为该股设定了“跑赢大盘”的评级和3.00美元的目标价。
Aprea Therapeutics Stock Performance
Aprea治疗公司股票表现
About Aprea Therapeutics
关于Aprea治疗公司
(Get Rating)
(获取评级)
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
Aprea治疗公司是一家临床阶段的生物制药公司，专注于开发和商业化针对DNA损伤反应通路的新型癌症疗法。它的主要候选产品是ATRN-119，这是一种口服ATR抑制剂，正在进行1/2a期临床试验，用于治疗晚期实体肿瘤患者。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免费获取StockNews.com关于Aprea治疗公司(APRE)的研究报告
- 随着管理层重组，股市能否迅速反弹？
- MarketBeat：回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖，但仍被高估吗？
Want to see what other hedge funds are holding APRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating).
想看看其他对冲基金持有APRE吗？访问HoldingsChannel.com获取Aprea治疗公司(纳斯达克：APRE-GET评级)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Aprea治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aprea治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧